Chronic Coronary
Disease Management
A practical approach to stable ischemic heart disease: lifestyle, medications that prolong life, and when to revascularize.
What Is Chronic Coronary Disease?
Chronic coronary disease (CCD), also called stable ischemic heart disease, is a long-standing condition in which fixed atherosclerotic plaque narrows the coronary arteries. The result is a mismatch between myocardial oxygen supply and demand during exertion.
The Supply–Demand Mismatch
Two Goals of Therapy
Core Rule: Optimal Medical Therapy First
The ISCHEMIA and COURAGE trials showed that in stable patients, an initial invasive strategy did not reduce death or MI compared to optimal medical therapy. PCI relieves angina but does not prolong life in stable disease.
The ABCDE Framework
Distinction: Stable vs Acute Coronary Syndrome
| Stable Angina (CCD) | Acute Coronary Syndrome | |
|---|---|---|
| Trigger | Predictable exertion | At rest / crescendo |
| Relief | Rest or nitroglycerin | Often not relieved by rest |
| Troponin | Normal | May be elevated |
| Pathology | Fixed plaque | Plaque rupture, thrombus |
| Disposition | Outpatient GDMT | Emergent, admit |
How to Approach a CCD Patient
Drugs That Prolong Life
Lipid Targets: High-Intensity Statin
All CCD patients are in a secondary prevention group. Start a high-intensity statin aiming for at least a 50% LDL reduction. Goal: \( \text{LDL-C} < 70 \) mg/dL, and many guidelines now target \( \text{LDL-C} < 55 \) mg/dL in very high-risk patients.
Worked Example: New Diagnosis
Worked Example: Refractory Angina
Worked Example: PCI or CABG?
Common Mistakes
Summary: Drug Roles
| Drug Class | Survival | Symptoms |
|---|---|---|
| Aspirin | Yes | No |
| High-intensity statin | Yes | No |
| ACEi / ARB (DM, HTN, low EF) | Yes | No |
| β-blocker | Yes (post-MI) | Yes |
| Nitrates | No | Yes |
| CCB / Ranolazine | No | Yes |
Question 1 of 5
A 62-year-old man with stable angina is started on therapy. Which medication is given primarily to reduce mortality, not symptoms?
Question 2 of 5
A stable CCD patient with single-vessel reversible ischemia asks if a stent will help him "live longer." What is the best response?
Question 3 of 5
Which first-line antianginal also provides a mortality benefit in patients with a prior myocardial infarction?
Question 4 of 5
A diabetic patient with refractory angina has three-vessel disease, a proximal LAD lesion, and \( \text{LVEF} = 30\% \). Which revascularization is preferred?
Question 5 of 5
A CCD patient on a maximally tolerated statin still has \( \text{LDL-C} = 95 \) mg/dL. What is the best next step?